- Home
- PBYI vs TVRD Comparison
PBYI vs TVRD Comparison
Compare PBYI & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- TVRD
- Stock Information
- Founded
- PBYI 2010
- TVRD 2017
- Country
- PBYI United States
- TVRD United States
- Employees
- PBYI N/A
- TVRD N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- TVRD Biotechnology: Pharmaceutical Preparations
- Sector
- PBYI Health Care
- TVRD Health Care
- Exchange
- PBYI Nasdaq
- TVRD Nasdaq
- Market Cap
- PBYI 263.4M
- TVRD 246.5M
- IPO Year
- PBYI N/A
- TVRD N/A
- Fundamental
- Price
- PBYI $4.95
- TVRD $4.22
- Analyst Decision
- PBYI Strong Buy
- TVRD Buy
- Analyst Count
- PBYI 1
- TVRD 7
- Target Price
- PBYI $7.00
- TVRD $51.67
- AVG Volume (30 Days)
- PBYI 418.9K
- TVRD 728.2K
- Earning Date
- PBYI 11-06-2025
- TVRD 11-21-2025
- Dividend Yield
- PBYI N/A
- TVRD N/A
- EPS Growth
- PBYI 434.29
- TVRD N/A
- EPS
- PBYI 0.97
- TVRD N/A
- Revenue
- PBYI $238,062,000.00
- TVRD N/A
- Revenue This Year
- PBYI N/A
- TVRD N/A
- Revenue Next Year
- PBYI N/A
- TVRD N/A
- P/E Ratio
- PBYI $5.08
- TVRD N/A
- Revenue Growth
- PBYI 8.63
- TVRD N/A
- 52 Week Low
- PBYI $2.32
- TVRD $4.16
- 52 Week High
- PBYI $6.07
- TVRD $43.65
- Technical
- Relative Strength Index (RSI)
- PBYI 45.94
- TVRD 19.29
- Support Level
- PBYI $5.14
- TVRD $4.63
- Resistance Level
- PBYI $5.52
- TVRD $5.00
- Average True Range (ATR)
- PBYI 0.25
- TVRD 0.40
- MACD
- PBYI -0.06
- TVRD 0.40
- Stochastic Oscillator
- PBYI 17.82
- TVRD 2.41
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.